Showing 34,847 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Neurological & cognitive problems

What Criteria Should Describe HIV-Related Cognitive Impairment?

Editor's pick
TheBodyPro
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Nutrition

Support for healthy eating improves health outcomes among people with HIV

News
21 June 2024
Injectable & long-acting PrEP

Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Editor's pick
AVAC
20 June 2024
Injectable & long-acting PrEP

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Editor's pick
Gilead Sciences press release
20 June 2024
Mpox (monkeypox)

South Africa Waits for Mpox Vaccines After Confirming Seven ‘Severe Cases’

Editor's pick
Health Policy Watch
20 June 2024
Bad science & bogus treatments

Old report about overseas Filipino workers with HIV falsely linked to Dubai

Editor's pick
AFP Factcheck
20 June 2024
HIV prevention policy

HIV prevention drug uptake is slow. Can offering choices change that?

Editor's pick
Devex (requires free registration)
20 June 2024
Liver disease

Most liver disease in people with HIV in low and middle-income countries is caused by metabolic disorders

News
20 June 2024
HIV testing programmes & uptake

In South Africa, traditional healers join the fight against HIV

Editor's pick
Associated Press
19 June 2024
Transgender people

Are trans men being forgotten in conversations about HIV prevention?

Editor's pick
Faculty of Public Health
19 June 2024
Young people

Caring, non-judgemental staff are the “magic ingredient” of youth-friendly HIV services

Editor's pick
Be In The Know
19 June 2024
Improving HIV care

South Africa clinics pilot Undetectable equals Untransmittable app to support HIV counselling

News
19 June 2024

HIV and breastfeeding – HIV update, 18 June 2024

June 2024
Cardiovascular disease

Why a major finding on HIV and statins may not be that relevant in South Africa

Editor's pick
Spotlight
18 June 2024
Men who have sex with men (MSM)

Local Laws, Policies, and State-Level Politics Are Associated With PrEP Use Among Younger LGBTQ+ People

Editor's pick
TheBodyPro
18 June 2024
Pregnancy and vertical transmission

Why Does It Take So Long to Gather Antiretroviral Drug Safety Data for Pregnant People With HIV in the U.S.?

Editor's pick
TheBodyPro
18 June 2024
Circumcision

Medical circumcision reduces HIV risk for gay and bisexual men - but only for tops

News
18 June 2024
People who inject drugs

Community-based early HIV testing and treatment could successfully manage and prevent emerging HIV outbreaks among people who inject drugs, study suggests

Editor's pick
University of Bristol
17 June 2024
Activism & civil society

Meet Kenya’s inspiring HIV peer educators

Editor's pick
Be In The Know
17 June 2024
Government, leadership & policy

Welcome progress, but time to start doing things differently - what next for the HIV response in the UK

Editor's pick
National AIDS Trust
17 June 2024